Incentives and reminders to help people take HIV medicines regularly
Official title: INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)
Funded at Rand Corporation · NIH-11378660 · Data updated 2026-11-12
This project uses daily reminders and small rewards to help people living with HIV keep a regular antiretroviral pill-taking routine.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rand Corporation NIH-funded |
| Lab location | 1 site (Santa Monica, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $106,052 |
| NIH project number | 3R01MH135751-02S1 |
| Project ID | NIH-11378660 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults living with HIV who are prescribed daily antiretroviral therapy and want help building a pill-taking routine.
✕Less likely to help
People who already take ART reliably every day or who cannot receive mobile messages or accept small incentives may be unlikely to benefit from this approach.
What this research studies
You’ll pick an existing daily habit (an "anchor") to pair with taking your HIV pills so taking them becomes automatic. Some participants will get daily reminder messages for three months to help stick to their plan, and others will get the same messages plus small monthly prizes when they take pills around their anchor. The team developed this approach after a successful pilot and will follow participants over time to see if routines and medication adherence improve. The goal is to make pill-taking easier and more automatic so it requires less effort.
Why it matters
Potential benefit: If successful, this approach could help more people with HIV keep viral suppression by making daily ART adherence easier.
How similar studies have gone: A prior R34 pilot by the same team showed this anchoring-plus-behavioral-economics approach could establish pill-taking routines, but larger trials are still needed.
Where this research is happening
-
Rand Corporation
Santa Monica, United States Active
Researchers
- Principal investigator: Linnemayr, Sebastian — Rand Corporation
- Study coordinator: Linnemayr, Sebastian
Related research
Other NIH-funded projects on the same topics.
-
Understanding why patients with blood cancers start and stick with oral cancer medicines
A study to learn what helps or hinders Black patients with blood cancers in starting and continuing their prescribed oral cancer medicines.
-
Incentives and Anchoring to Improve Long-term HIV Medication Adherence
A study tests a simple, daily habit plan combined with friendly reminders and small rewards to help people living with HIV take their ART pills on time.
-
WeCare: a combined mental health and HIV medication support program for high-risk men
A patient-friendly program called WeCare aims to support mental health and improve adherence to HIV meds among high-risk men in settings with limited resources.
-
Medication adherence to epilepsy medicines during pregnancy and related birth outcomes
This project looks at how well pregnant people with epilepsy take their anti-seizure medicines and what happens to their babies.
-
Adaptive mHealth Support to Help Teens with Asthma Stick to Their Inhalers
A multi-site study tests a flexible smartphone-based program to help adolescents with asthma take their inhaled meds more consistently.
-
Reducing High Blood Pressure in Men in Manual Jobs with a Mobile Stress and Medication Adherence Program
A mobile stress-management and medication adherence program aims to help men in manual and trade jobs lower their blood pressure and stay on their prescribed treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.